Clinical trial
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate…
NCT00291369 · Centre Leon Berard, Other · Completed
Key facts
| NCT number | NCT00291369 |
|---|---|
| Title | Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis |
| Official title | PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis |
| Lead sponsor | Centre Leon Berard, Other |
| Collaborators | French Immunotherapy Intergroup SCAPP (Sub-Cutaneous Administration Proleukin Program) |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Interleukin-2, Interferon alfa, medroxyprogesterone acetate |
| Enrollment | 456 |
| Start date | Dec 1, 1999 |
| Completion | Feb 1, 2005 |
| First posted | Feb 14, 2006 |
| Last update posted | Feb 16, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: